There is no difference in the pre-DARA-treatment levels of the complement inhibitory proteins CD55 and CD59 expression on MM cells when comparing responders to non-responders, but there is an upregulation of CD55 and CD59 at the time of progression during DARA monotherapy [11]. Here, CD55 is linked to Miyoshi myopathy.